Bachurin, S. O. published the artcileRole of dopamine uptake system in the development of experimental parkinsonism induced by 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and its pyridine analogs, Application of 1,1′-Diphenyl-[4,4′-bipyridine]-1,1′-diium chloride, the publication is Doklady Akademii Nauk SSSR (1989), 307(3), 740-3 [Biochem.], database is CAplus.
The effects of the title drug (I), an agent inducing exptl. parkinsonism, and 8 of its pyridine and dipyridyl analogs on brain content of monoamines, behavior, and synaptosomal reuptake of dopamine were studied in mice. Two daily doses of the agents at 80-90% of their LD50 did not affect (except I) the brain levels of noradrenaline, dopamine, and serotonin within 5-7 days and the behavior within 3 mo. In vitro, all the agents reversibly and competitively inhibited [14C]dopamine uptake by the brain synaptosomes. The tetradehydro-I was the strongest inhibitor which is also an in vivo metabolite of I. The inhibitory effects of the other agents were partially related to their structure and lipophilicity.
Doklady Akademii Nauk SSSR published new progress about 47369-00-6. 47369-00-6 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Benzene,Organic ligands for MOF materials,Nitrogen containing MOF ligands,Nitrogen containing MOF ligands, name is 1,1′-Diphenyl-[4,4′-bipyridine]-1,1′-diium chloride, and the molecular formula is C22H18Cl2N2, Application of 1,1′-Diphenyl-[4,4′-bipyridine]-1,1′-diium chloride.
Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem